Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Theravance Biopharma Inc. | Izencitinib | Crohn's Disease | Phase 2 | Trial Discontinued | Oral | Gastroenterology |
| Theriva Biologics, Inc. | VCN-01 (VIRAGE) | Metastatic PDAC | Phase 2b | Data Released | intravenous | Oncology |
| Theriva Biologics, Inc. | Ribaxamase (SYN-004) | C. difficile Infection | Phase 2b | Looking for Funding | Oral | Antibiotic |
| Theriva Biologics, Inc. | SYN-010 | Constipation-Predominant Irritable Bowel Syndrome (C-IBS) | Phase 2b | Trial Discontinued | oral | Gastroenterology |
| Third Harmonic Bio Inc. | THB335 | Mast cell-mediated inflammatory diseases | Phase 2 | Looking for Funding | Oral | Immunology |
| Tivic Health Systems Inc. | Entolimod | Acute radiation syndrome (ARS) | Phase 3 | Ongoing | Intramuscular | Oncology |
| Tiziana Life Sciences Ltd | Milciclib and NEXAVAR (sorafenib) | Hepatocellular carcinoma (HCC) | Phase 2b | Milciclib oral NEXAVAR oral | Oncology | |
| Tiziana Life Sciences Ltd | Nasal Foralumab - (Healey ALS) | Amyotrophic lateral sclerosis (ALS) | Phase 2 | Ongoing | Intranasal | Neurology |
